CA2325995A1 - Antagonistes de l'hormone liberant la gonadotropine (gnrh) - Google Patents

Antagonistes de l'hormone liberant la gonadotropine (gnrh) Download PDF

Info

Publication number
CA2325995A1
CA2325995A1 CA002325995A CA2325995A CA2325995A1 CA 2325995 A1 CA2325995 A1 CA 2325995A1 CA 002325995 A CA002325995 A CA 002325995A CA 2325995 A CA2325995 A CA 2325995A CA 2325995 A1 CA2325995 A1 CA 2325995A1
Authority
CA
Canada
Prior art keywords
alkyl
substituted
aryl
compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002325995A
Other languages
English (en)
Inventor
Thomas F. Walsh
Feroze Ujjainwalla
Mark T. Goulet
Jonathan R. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9811286.5A external-priority patent/GB9811286D0/en
Application filed by Individual filed Critical Individual
Publication of CA2325995A1 publication Critical patent/CA2325995A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention porte sur des composés de la formule (I) et sur leurs sels pharmaceutiquement acceptables qui sont utilisés comme antagonistes de GnRH et, en conséquence, dans le traitement d'états relatifs à l'hormone sexuelle et à d'autres hormones chez l'homme et chez la femme.
CA002325995A 1998-04-02 1999-03-29 Antagonistes de l'hormone liberant la gonadotropine (gnrh) Abandoned CA2325995A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8039998P 1998-04-02 1998-04-02
US60/080,399 1998-04-02
GB9811286.5 1998-05-26
GBGB9811286.5A GB9811286D0 (en) 1998-05-26 1998-05-26 Antagonists of gonadotropin releasing hormone
PCT/US1999/006713 WO1999051231A1 (fr) 1998-04-02 1999-03-29 Antagonistes de l'hormone liberant la gonadotropine (gnrh)

Publications (1)

Publication Number Publication Date
CA2325995A1 true CA2325995A1 (fr) 1999-10-14

Family

ID=26313744

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002325995A Abandoned CA2325995A1 (fr) 1998-04-02 1999-03-29 Antagonistes de l'hormone liberant la gonadotropine (gnrh)

Country Status (5)

Country Link
EP (1) EP1067929A1 (fr)
JP (1) JP2002510628A (fr)
AU (1) AU3117899A (fr)
CA (1) CA2325995A1 (fr)
WO (1) WO1999051231A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1990343B1 (fr) 1999-12-24 2012-04-04 Aventis Pharma Limited Azaindoles
GB0022670D0 (en) 2000-09-15 2000-11-01 Astrazeneca Ab Molecules
SE0100566D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
SE0101692D0 (sv) 2001-05-14 2001-05-14 Astrazeneca Ab Compounds
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0219472D0 (en) 2002-08-21 2002-10-02 Astrazeneca Ab Chemical compounds
TW200413351A (en) 2002-08-21 2004-08-01 Astrazeneca Ab Chemical compounds
TW200407127A (en) 2002-08-21 2004-05-16 Astrazeneca Ab Chemical compounds
DE60318716T2 (de) 2002-08-21 2009-01-08 Astrazeneca Ab Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren
ES2286493T3 (es) 2002-08-21 2007-12-01 Astrazeneca Ab Derivados de pirazol como inhibidores de gnrh.
PL1696920T3 (pl) 2003-12-19 2015-03-31 Plexxikon Inc Związki i sposoby opracowywania modulatorów Ret
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
DE102004033902A1 (de) 2004-07-14 2006-02-16 Zentaris Gmbh Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's)
CA2628179A1 (fr) 2005-11-15 2007-05-24 Vertex Pharmaceuticals Incorporated Azaindazoles utiles en tant qu'inhibiteurs de kinases
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP2095818A1 (fr) 2008-02-29 2009-09-02 AEterna Zentaris GmbH Utilisation d'antagonistes LHRH dans des doses n'impliquant pas de castration
HUE027598T2 (en) 2009-04-03 2016-10-28 Hoffmann La Roche Propane-1-sulfonic acid {3- [5- (4-chlorophenyl) -1H-pyrrolo [2,3-B] pyridine-3-carbonyl] -2,4-difluorophenyl} amide compositions and their uses
ES2633317T3 (es) 2009-11-06 2017-09-20 Plexxikon, Inc. Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
MA34948B1 (fr) 2011-02-07 2014-03-01 Plexxikon Inc Composes et procedes de modulation de kinase, et leurs indications
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732969B1 (fr) * 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU7333496A (en) * 1995-10-19 1997-05-07 Takeda Chemical Industries Ltd. Quinoline derivatives as gnrh antagonists
US5849764A (en) * 1995-12-14 1998-12-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone

Also Published As

Publication number Publication date
EP1067929A1 (fr) 2001-01-17
AU3117899A (en) 1999-10-25
JP2002510628A (ja) 2002-04-09
WO1999051231A1 (fr) 1999-10-14

Similar Documents

Publication Publication Date Title
US6025366A (en) Antagonists of gonadotropin releasing hormone
CA2326185A1 (fr) Antagonistes de l'hormone liberant la gonadotropine (gnrh)
CA2326143A1 (fr) Antagonistes de l'hormone liberant la gonadotropine (gnrh)
US6288078B1 (en) 6-azaindole compounds as antagonists of gonadotropin releasing hormone
CA2326139A1 (fr) Antagonistes de la gonadoliberine
AU3117899A (en) Antagonists of gonadotropin releasing hormone
CA2326140A1 (fr) Antagonistes de l'hormone liberant la gonadotropine (gnrh)
CA2366615A1 (fr) Composes 6-azaindole utilises comme antagonistes d'une hormone liberant la gonadotropine
CA2326184A1 (fr) Antagonistes de l'hormone liberant la gonadotropine (gnrh)
US6077847A (en) Antagonists of gonadotropin releasing hormone
US5985892A (en) Antagonists of gonadotropin releasing hormone
US5998432A (en) Antagonists of gonadotropin releasing hormone
US6180642B1 (en) 6-azaindole compounds as antagonists of Gonadotropin releasing hormone
AU3868800A (en) 6-azaindole compounds as antagonists of gonadotropin releasing hormone
CA2367126A1 (fr) Composes de 6-azaindole comme antagonistes de la gonadoliberine
CA2367116A1 (fr) Composes 6-azaindole utilises comme antagonistes d'une hormone liberant la gonadotropine
US6110931A (en) Antagonists of gonadotropin releasing hormone
US6228867B1 (en) Antagonists of gonadotropin releasing hormone

Legal Events

Date Code Title Description
FZDE Dead